Irbesartan + Hidroclorotiazida Alter

Irbesartan, the active ingredient in Irbesartan + Hidroclorotiazida Alter, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for systemic use. It helps lower high blood pressure in adult patients. GNH USA supplies Irbesartan + Hidroclorotiazida Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used in the management of hypertension, acting on the renin‑angiotensin‑aldosterone system and fluid balance.

- Primary hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. - Hypertension with fluid retention: improves blood pressure control by adding diuretic effect. - Resistant hypertension: provides additional lowering when monotherapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Increased urination or mild electrolyte changes. - Fatigue or mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia). - Acute kidney injury or worsening renal function. - Hyperkalemia, especially when combined with potassium‑sparing agents. - Angioedema or severe allergic reactions. - Blood dyscrasias such as agranulocytosis.

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and eGFR regularly. - Electrolyte balance: check potassium and sodium levels, especially in patients on other diuretics. - Caution in elderly: start at lower doses to reduce risk of hypotension. - Avoid in severe hepatic impairment: drug metabolism may be altered. - Do not combine with potassium‑sparing diuretics or supplements without supervision. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Lithium: may raise lithium levels, leading to toxicity. - NSAIDs: can blunt antihypertensive effect and affect renal function. - Potassium supplements or ACE inhibitors: risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Other diuretics (non‑potassium‑sparing): monitor electrolytes and volume status. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce irbesartan effectiveness.